HC Wainwright Comments on Tarsus Pharmaceuticals, Inc.’s Q2 2024 Earnings (NASDAQ:TARS)

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSFree Report) – HC Wainwright lifted their Q2 2024 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research report issued on Monday, May 13th. HC Wainwright analyst O. Livnat now forecasts that the company will earn ($0.90) per share for the quarter, up from their prior estimate of ($1.08). HC Wainwright currently has a “Buy” rating and a $61.00 target price on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($4.03) per share. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q3 2024 earnings at ($0.89) EPS, Q4 2024 earnings at ($0.90) EPS, FY2024 earnings at ($3.70) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at $2.79 EPS, FY2027 earnings at $5.14 EPS and FY2028 earnings at $5.69 EPS.

Several other analysts have also weighed in on the stock. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the company a “neutral” rating in a research note on Thursday, February 29th. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $59.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, May 9th. Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Finally, Barclays lifted their price target on Tarsus Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a report on Friday, May 10th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Tarsus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $50.38.

Read Our Latest Stock Report on Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Stock Down 1.0 %

Shares of TARS stock opened at $37.99 on Wednesday. Tarsus Pharmaceuticals has a 12-month low of $12.57 and a 12-month high of $42.50. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.01 and a quick ratio of 7.92. The firm has a 50-day moving average price of $34.31 and a 200 day moving average price of $26.84.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($1.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.06. The company had revenue of $13.08 million for the quarter, compared to the consensus estimate of $4.63 million. During the same period in the previous year, the business posted ($0.49) earnings per share.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its position in shares of Tarsus Pharmaceuticals by 362.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,832 shares of the company’s stock worth $78,000 after buying an additional 3,004 shares during the period. Tower Research Capital LLC TRC lifted its stake in Tarsus Pharmaceuticals by 22.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,560 shares of the company’s stock valued at $92,000 after acquiring an additional 824 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Tarsus Pharmaceuticals by 65.1% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,306 shares of the company’s stock worth $94,000 after acquiring an additional 2,092 shares during the last quarter. Raymond James & Associates acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $180,000. Finally, Ieq Capital LLC acquired a new position in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $193,000. Institutional investors and hedge funds own 90.01% of the company’s stock.

Insiders Place Their Bets

In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the completion of the sale, the chief operating officer now owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel Bryan Wahl sold 4,436 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total value of $135,741.60. Following the completion of the transaction, the general counsel now owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Seshadri Neervannan sold 4,879 shares of the business’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the completion of the transaction, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at approximately $1,981,870.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 24,496 shares of company stock valued at $749,578. Company insiders own 11.54% of the company’s stock.

About Tarsus Pharmaceuticals

(Get Free Report)

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Further Reading

Earnings History and Estimates for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.